Biocept (BIOC) & TrovaGene (NASDAQ:TROV) Head to Head Survey

Biocept (NASDAQ: BIOC) and TrovaGene (NASDAQ:TROV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitabiliy, analyst recommendations, risk, institutional ownership and dividends.

Valuation & Earnings

This table compares Biocept and TrovaGene’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Biocept $4.68 million 8.64 -$17.28 million ($1.65) -0.92
TrovaGene $355,623.00 97.54 -$35.52 million ($1.34) -0.84

Biocept has higher revenue and earnings than TrovaGene. Biocept is trading at a lower price-to-earnings ratio than TrovaGene, indicating that it is currently the more affordable of the two stocks.


This table compares Biocept and TrovaGene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biocept -383.29% -1,177.51% -204.76%
TrovaGene -10,938.20% -162.31% -77.68%

Insider and Institutional Ownership

14.6% of Biocept shares are owned by institutional investors. Comparatively, 18.2% of TrovaGene shares are owned by institutional investors. 7.7% of Biocept shares are owned by company insiders. Comparatively, 7.4% of TrovaGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Biocept has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500. Comparatively, TrovaGene has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Biocept and TrovaGene, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biocept 0 0 3 0 3.00
TrovaGene 1 0 2 0 2.33

Biocept currently has a consensus price target of $2.50, suggesting a potential upside of 64.47%. TrovaGene has a consensus price target of $4.45, suggesting a potential upside of 297.32%. Given TrovaGene’s higher probable upside, analysts plainly believe TrovaGene is more favorable than Biocept.


Biocept beats TrovaGene on 7 of the 13 factors compared between the two stocks.

Biocept Company Profile

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

TrovaGene Company Profile

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with's FREE daily email newsletter.

Leave a Reply